The Antigagging Effect of Granisetron (Kytril), an Antiemetic Drug, in Dental Situations
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00502437|
Recruitment Status : Unknown
Verified June 2007 by Hadassah Medical Organization.
Recruitment status was: Not yet recruiting
First Posted : July 17, 2007
Last Update Posted : November 30, 2010
Antigagging effect of kytril (granisetron) an antiemetic drug in dental situations
Gagging in dental situations can be a problem to the patient and the operating dentist. There are not proven methods of eliminating this reflex which sometimes will not allow routine quality dental care.
Pharmacological and behavioral approaches to eliminate this reflex have been tried with limited success.
This suggested study will test a potent antiemetic drug used in other clinical situations such as antineoplastic treatment. Granisetron is a potential antagonist for the 5-hydroxytryptamine3-receptor - 5HT(3), The drug binds to the receptor and blocks the effect of nausea and vomiting. Kytril mechanism of action was successfully proven for various medical situations as a potential antiemetic agent. Our Center for dental sedation and anesthesia in the oral medicine department have received approval to use Granisetron as an antigagging drug in dental situations based on several pilot studies conducted in other medical centers in different clinical situations such as strabismus corrections, post hysterectomy and others. Our preliminary clinical impression is that pre-emptive IV administration of this drug to patients with increased gag reflex is beneficial.
In our research we try to investigate the possibility of using kytril in dental situations.
In the first stage of this research we will study the INTRAVENOUS use of this drug and its effects On normal subjects compare them to themselves with placebo. According to the results of this study we will go on to the second stage of the research and try the same drug under oral administration.
The purpose of this study is to test the antigagging effect of this drug in a controlled manner in dental situations.
Our working hypothesis is that administration of this drug in dental situations with success, will allow many patients to receive good dental care
|Condition or disease||Intervention/treatment||Phase|
|Antiggaging Effect Antiemetic Granisetron Gag Reflex Dental Situations||Drug: GRANISETRON||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Crossover Assignment|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00502437
|Contact: Eliezer Kaufman, Professoremail@example.com|
|Contact: Silvina Friedlander-Barenboim, DMDfirstname.lastname@example.org|
|Hadassah Medical Organization||Not yet recruiting|
|Contact: Arik Tzukert, DMD 00 972 2 6776095 email@example.com|
|Contact: Hadas Lemberg, PhD 00 972 2 6777572 firstname.lastname@example.org|
|Principal Investigator: Eliezer Kaufman, DMD|
|Principal Investigator:||Eliezer Kaufman, DMD||Hadassah Medical Organization|